Ken Griffin Bellus Health Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$7.14 - $8.53 $870,144 - $1.04 Million	121,869 Added 2.92%	4,290,398 $30.9 Million
Q4 2022 Feb 14, 2023	BUY	$8.22 - $10.76 $1.82 Million - $2.39 Million	221,755 Added 5.62%	4,168,529 $34.3 Million
Q3 2022 Nov 14, 2022	SELL	$8.95 - $12.0 $5.59 Million - $7.49 Million	-624,230 Reduced 13.66%	3,946,774 $41.7 Million
Q2 2022 Aug 15, 2022	SELL	$6.46 - $10.02 $2.13 Million - $3.3 Million	-329,376 Reduced 6.72%	4,571,004 $42.2 Million
Q1 2022 May 16, 2022	BUY	$5.56 - $7.99 $327,233 - $470,251	58,855 Added 1.22%	4,900,380 $33.7 Million
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $9.53 Million - $15 Million	1,812,356 Added 59.83%	4,841,525 $39 Million
Q3 2021 Nov 15, 2021	BUY	$2.7 - $6.64 $1.94 Million - $4.78 Million	719,341 Added 31.14%	3,029,169 $18.6 Million
Q2 2021 Aug 16, 2021	BUY	$3.11 - $4.61 $5.12 Million - $7.6 Million	1,647,612 Added 248.8%	2,309,828 $7.18 Million
Q1 2021 May 17, 2021	SELL	$3.03 - $4.58 $1.49 Million - $2.25 Million	-491,539 Reduced 42.6%	662,216 $2.54 Million
Q4 2020 Feb 16, 2021	BUY	$2.27 - $3.3 $467,560 - $679,714	205,974 Added 21.73%	1,153,755 $3.53 Million
Q3 2020 Nov 16, 2020	BUY	$2.14 - $12.02 $520,373 - $2.92 Million	243,165 Added 34.51%	947,781 $2.16 Million
Q2 2020 Aug 14, 2020	BUY	$8.88 - $11.15 $999,301 - $1.25 Million	112,534 Added 19.01%	704,616 $7.27 Million
Q1 2020 May 15, 2020	SELL	$5.77 - $10.85 $32,144 - $60,445	-5,571 Reduced 0.93%	592,082 $5.89 Million
Q4 2019 Feb 14, 2020	SELL	$5.76 - $7.6 $1.84 Million - $2.42 Million	-318,983 Reduced 34.8%	597,653 $4.52 Million
Q3 2019 Nov 14, 2019	BUY	$6.24 - $8.84 $5.72 Million - $8.1 Million	916,636 New	916,636 $5.86 Million

Others Institutions Holding BLU

# of Institutions

Shares Held

128K

Call Options Held

Put Options Held

Pendal Group LTD

128K
Shares

$0
0.01% of portfolio

View Full List

About BELLUS Health Inc.

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

More about BLU

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account